Lataa...
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
The α(2)-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in...
Tallennettuna:
| Julkaisussa: | Neuropsychiatr Dis Treat |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455846/ https://ncbi.nlm.nih.gov/pubmed/26064054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S65735 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|